{
    "Trade/Device Name(s)": [
        "Fenom Pro\u2122 Nitric Oxide Test"
    ],
    "Submitter Information": "Spirosure, Inc.",
    "510(k) Number": "K182874",
    "Predicate Device Reference 510(k) Number(s)": [
        "K072816"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MXA"
    ],
    "Summary Letter Date": "January 11, 2019",
    "Summary Letter Received Date": "January 15, 2019",
    "Submission Date": "October 11, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.3080"
    ],
    "Regulation Name(s)": [
        "Breath nitric oxide test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "Fractional exhaled nitric oxide (FeNO)",
        "Nitric oxide (NO)"
    ],
    "Specimen Type(s)": [
        "Exhaled human breath"
    ],
    "Specimen Container(s)": [
        "Breath tube",
        "Mouthpiece",
        "Handpiece with breath conditioning cartridge"
    ],
    "Instrument(s)/Platform(s)": [
        "Fenom Pro\u2122 main unit"
    ],
    "Method(s)/Technology(ies)": [
        "Solid-state electrochemical sensor",
        "Potentiometric sensor technology"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Consumable",
        "Cartridge",
        "Mouthpiece"
    ],
    "Document Summary": "FDA 510(k) summary for Fenom Pro\u2122 portable breath analyzer measuring fractional exhaled nitric oxide (FeNO) using solid-state electrochemical technology for asthma therapeutic monitoring",
    "Indications for Use Summary": "Measures fractional exhaled nitric oxide in human breath as an adjunct for monitoring therapeutic effects of anti-inflammatory pharmacological therapy in asthma patients with elevated FeNO; suitable for children (7-17 years) and adults (18+), used in point-of-care healthcare settings under professional supervision",
    "fda_folder": "Toxicology"
}